| P/E (FY) | — | Sales (TTM) | $156.1M |
| Earnings (TTM) | -$395.3M | ROE | −16.07% |
| Net Margin | −277.47% | ROIC | −19.24% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 38.37% |
GRAIL is a commercial-stage healthcare company providing multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50, and a diagnostic aid to accelerate resolution for patients with clinical suspicion of cancer. The company also provides development services and a precision oncology portfolio based on an RUO-targeted methylation platform for prognostication, risk stratification, minimal residual disease detection, and recurrence monitoring.
| Market Cap | $2.76B | Trading Days | 521 |
| 52W High | 118.84 |
| 52W Low | 29.95 |
| % Off High | −45.79% |
| YTD | −24.73% | 1Y | 68.33% |
| Since incept. (ann.) | 89.22% |
Screening Revenue 94% · Developmental Services Revenue 6%
| Ann. Volatility (1Y) | 97.88% | Ann. Volatility (3Y) | 103.70% |
| Sharpe (1Y) | 1.09 | Sharpe (3Y) | 1.16 |
| Max Drawdown (1Y) | −62.92% | Max Drawdown (3Y) | −62.92% |
| Beta (3Y, vs SPY) | 3.24 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| BLLN | BillionToOne, Inc. | $2.84B | 380.6 |
| FTRE | Fortrea Holdings Inc. | $1.96B | — |
| CELC | Celcuity Inc. | $4.02B | — |
| CDNA | CareDx, Inc. | $1.85B | — |
| CAI | Caris Life Sciences, Inc. | $4.41B | — |
| VCYT | VERACYTE, INC. | $4.44B | 67.9 |
| RDNT | RadNet, Inc. | $4.97B | — |
| PSNL | Personalis, Inc. | $1.24B | — |
| LMRI | Lumexa Imaging Holdings, Inc. | $1.05B | — |
| CSTL | CASTLE BIOSCIENCES INC | $724.6M | — |
| FLGT | Fulgent Genetics, Inc. | $557.5M | — |
| GH |
| Guardant Health, Inc. |
| $19.04B |
| — |
